USA flag logo/image

An Official Website of the United States Government

Controlled Release of Topical Nitric Oxide for Treating Cutaneous Injuries

Award Information

Agency:
Department of Defense
Branch:
Army
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
A2-4861
Solicitation Year:
2010
Solicitation Topic Code:
A10-160
Solicitation Number:
2010.3
Small Business Information
Zeomedix
26 Ashlawn Circle Malvern, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: Controlled Release of Topical Nitric Oxide for Treating Cutaneous Injuries
Agency / Branch: DOD / ARMY
Contract: W81XWH-11-C-0031
Award Amount: $780,029.00
 

Abstract:

In this proposal Zeomedix proposes to develop a dressing for infected trauma wounds based on its zeolite encapsulating nitric oxide (NO) technology. Nitric oxide has been shown to enhance the wound healing process as well as act as a powerful antibacterial agent. However, delivery of nitric oxide to a wound area is extremely challenging because NO is a gas. Zeomedixs approach is to use zeolites that bind NO molecules when exposed to a stream of gaseous NO. When NO-loaded zeolites come in contact with water (or wound fluid), NO is released into the wound area. The overall goal of Zeomedixs Phase II project is to develop an optimal NO-zeolite wound dressing for treating infected acute wounds. Our technical approach can be organized into three steps: (1) Develop three different NO-zeolite wound dressing prototypes, consisting of NO-zeolite ointment enclosed within a semi-porous pouch, each having distinct nitric oxide release rates. (2) Characterize the storage stability, cytotoxicity, and antimicrobial efficacy of the prototypes against both planktonic microorganisms and bacterial biofilms in vitro. (3) Evaluate the ability of the two leading prototypes to reduce wound infection and improve wound healing in vivo using a full-thickness infected porcine wound model. The overall goal of Zeomedixf"ff3/4s Phase II project is to develop an optimal NO-zeolite wound dressing for treating infected acute wounds. Our technical approach can be organized into three steps: (1) Develop three different NO-zeolite wound dressing prototypes, consisting of NO-zeolite ointment enclosed within a semi-porous pouch, each having distinct nitric oxide release rates (2) Characterize the storage stability, cytotoxicity, and antimicrobial efficacy of the prototypes against both planktonic microorganisms and bacterial biofilms in vitro (3) Evaluate the ability of the two leading prototypes to reduce wound infection and improve wound healing in vivo using a full-thickness infected porcine wound model

Principal Investigator:

John Aybar
CEO
(610) 517-1878
aybarc@gmail.com

Business Contact:

John Aybar
CEO
(610) 517-7818
aybarc@gmail.com
Small Business Information at Submission:

Zeomedix, LLC
26 Ashlawn Circle Malvern, PA -

EIN/Tax ID: 264745889
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No